SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — Aug 3, 2015
AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: Aug. 3, 2015 · CIK: 0000946644 · Accession: 0000946644-15-000036
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-205228
Letter
Division of Corporation Finance Securities and Exchange Commission Re: Hemispherx Biopharma, Inc. Registration Statement on Form S-3 Filed June 25, 2015 File No. 333-205228
Dear Mr. Riedler:
Hemispherx Biopharma, Inc. (“Hemispherx”) hereby requests, pursuant to Rule 461 of Regulation C, that the effective date of the above referenced Registration Statement be accelerated so that it is declared effective at 4:00 p.m. on August 4, 2015 or as soon thereafter as practicable.
Hemispherx acknowledges that the disclosure in the filing is the responsibility of Hemispherx.
Hemispherx also represents to the Commission that should the Commission or the staff acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing and Hemispherx represents that it will not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Hemispherx further acknowledges, that the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective does not relieve Hemispherx from its full responsibility for the adequacy and accuracy of the disclosures in the filing.
Very truly yours,
HEMISPHERX BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm Accelerationrequest8-15S-3UnivShelf HEMISPHERX BIOPHARMA, INC. 1617 JFK Boulevard Philadelphia, Pennsylvania 19103 August 3, 2015 Jeffrey Riedler Assistant Director Division of Corporation Finance Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Hemispherx Biopharma, Inc. Registration Statement on Form S-3 Filed June 25, 2015 File No. 333-205228 Dear Mr. Riedler: Hemispherx Biopharma, Inc. (“Hemispherx”) hereby requests, pursuant to Rule 461 of Regulation C, that the effective date of the above referenced Registration Statement be accelerated so that it is declared effective at 4:00 p.m. on August 4, 2015 or as soon thereafter as practicable. Hemispherx acknowledges that the disclosure in the filing is the responsibility of Hemispherx. Hemispherx also represents to the Commission that should the Commission or the staff acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing and Hemispherx represents that it will not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Hemispherx further acknowledges, that the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective does not relieve Hemispherx from its full responsibility for the adequacy and accuracy of the disclosures in the filing. Very truly yours, HEMISPHERX BIOPHARMA, INC. By: /s/: William A. Carter William A. Carter, MD 419324 Chief Executive Officer 419324